{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:41:04Z","timestamp":1794580864243,"version":"4.9.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Living Cell Technologies"},{"name":"Auckland Hospital A+ Trust and Research Office"},{"name":"Department of Clinical Neuroscience"},{"name":"University of Cambridge, Cambridge","award":["CB2 0PY"],"award-info":[{"award-number":["CB2 0PY"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.parkreldis.2018.11.015","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T12:21:36Z","timestamp":1542111696000},"page":"88-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["A phase IIb, randomised, double-blind, placebo-controlled, dose-ranging investigation of the safety and efficacy of NTCELL\u00ae [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease"],"prefix":"10.1016","volume":"61","author":[{"given":"Barry","family":"Snow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin","family":"Mulroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Bok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BB Janice","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Frampton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Schweder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benson","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Finucane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.parkreldis.2018.11.015_bib1","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1602\/neurorx.1.4.382","article-title":"Cell therapy in Parkinson's disease","volume":"1","author":"Lindvall","year":"2004","journal-title":"NeuroRx"},{"issue":"23","key":"10.1016\/j.parkreldis.2018.11.015_bib2","doi-asserted-by":"crossref","first-page":"6544","DOI":"10.1073\/pnas.1605245113","article-title":"Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain","volume":"113","author":"Li","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.parkreldis.2018.11.015_bib3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jamaneurol.2013.4749","article-title":"Long-term clinical outcome of fetal cell transplantation for Parkinson disease two case reports","volume":"71","author":"Kefalopoulou","year":"2014","journal-title":"JAMA neurology"},{"issue":"Pt 2","key":"10.1016\/j.parkreldis.2018.11.015_bib4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/978-3-211-33081-4_16","article-title":"GDNF delivery for Parkinson's disease","volume":"97","author":"Patel","year":"2007","journal-title":"Acta Neurochir. Suppl."},{"issue":"12","key":"10.1016\/j.parkreldis.2018.11.015_bib5","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","article-title":"Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial","volume":"9","author":"Marks","year":"2010","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.parkreldis.2018.11.015_bib6","doi-asserted-by":"crossref","first-page":"065001","DOI":"10.1088\/1741-2560\/6\/6\/065001","article-title":"Encapsulated living choroid plexus cells: potential long-term treatments for central nervous system disease and trauma","volume":"6","author":"Skinner","year":"2009","journal-title":"J. Neural. Eng."},{"issue":"9","key":"10.1016\/j.parkreldis.2018.11.015_bib7","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1161\/01.STR.0000138954.25825.0b","article-title":"Intracerebral transplantation of porcine choroid plexus provides structural and functional neuroprotection in a rodent model of stroke","volume":"35","author":"Borlongan","year":"2004","journal-title":"Stroke"},{"issue":"16","key":"10.1016\/j.parkreldis.2018.11.015_bib8","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1097\/00001756-200411150-00018","article-title":"Neuroprotection by encapsulated choroid plexus in a rodent model of Huntington's disease","volume":"15","author":"Borlongan","year":"2004","journal-title":"Neuroreport"},{"issue":"3","key":"10.1016\/j.parkreldis.2018.11.015_bib9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3233\/JPD-130214","article-title":"Recovery of neurological functions in non-human primate model of Parkinson's disease by transplantation of encapsulated neonatal porcine choroid plexus cells","volume":"3","author":"Luo","year":"2013","journal-title":"J. Parkinson's Dis."},{"key":"10.1016\/j.parkreldis.2018.11.015_bib10","first-page":"873706","article-title":"Parkinson's disease and mesenchymal stem cells: potential for cell-based therapy","volume":"2012","author":"Kitada","year":"2012","journal-title":"Parkinsons Dis"},{"key":"10.1016\/j.parkreldis.2018.11.015_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.virusres.2016.08.012","article-title":"No PERV transmission during a clinical trial of pig islet cell transplantation","volume":"227","author":"Morozov","year":"2017","journal-title":"Virus Res."},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2018.11.015_bib12","first-page":"321","article-title":"Safety and clinical effects of NTCELL\u00ae [immunoprotected (alginate\u2010encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease (PD): 26 weeks follow\u2010up [abstract]","volume":"30","author":"Snow","year":"2015","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2018.11.015_bib13","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1037\/0735-7044.113.4.718","article-title":"Effects of regional striatal lesions on motor, motivational, and executive aspects of progressive-ratio performance in rats","volume":"113","author":"Eagle","year":"1999","journal-title":"Behav. Neurosci."},{"issue":"Pt 7","key":"10.1016\/j.parkreldis.2018.11.015_bib14","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/brain\/123.7.1442","article-title":"The influence of excitotoxic basal ganglia lesions on motor performance in the common marmoset","volume":"123","author":"Kendall","year":"2000","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.parkreldis.2018.11.015_bib15","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/j.1532-5415.1956.tb01168.x","article-title":"Effects of lesions in the putamen on involuntary movements and rigidity in Parkinson's disease","volume":"4","author":"Cooper","year":"1956","journal-title":"J. Am. Geriatr. Soc."},{"issue":"2","key":"10.1016\/j.parkreldis.2018.11.015_bib16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.14802\/jmd.16005","article-title":"Movement disorders following cerebrovascular lesion in the basal ganglia circuit","volume":"9","author":"Park","year":"2016","journal-title":"J Mov Disord"},{"issue":"Pt 4","key":"10.1016\/j.parkreldis.2018.11.015_bib17","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/brain\/117.4.859","article-title":"The behavioural and motor consequences of focal lesions of the basal ganglia in man","volume":"117","author":"Bhatia","year":"1994","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.parkreldis.2018.11.015_bib18","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.parkreldis.2012.10.021","article-title":"Levodopa-responsive Parkinsonism following bilateral putaminal hemorrhages","volume":"19","author":"Hatano","year":"2013","journal-title":"Park. Relat. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2018.11.015_bib19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm850","article-title":"Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease","volume":"9","author":"Gill","year":"2003","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.parkreldis.2018.11.015_bib20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ana.20737","article-title":"Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease","volume":"59","author":"Lang","year":"2006","journal-title":"Ann. Neurol."},{"issue":"Pt 8","key":"10.1016\/j.parkreldis.2018.11.015_bib21","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1093\/brain\/awt192","article-title":"Disease duration and the integrity of the nigrostriatal system in Parkinson's disease","volume":"136","author":"Kordower","year":"2013","journal-title":"Brain"},{"issue":"163","key":"10.1016\/j.parkreldis.2018.11.015_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004676","article-title":"\u03b1-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons","volume":"4","author":"Decressac","year":"2012","journal-title":"Sci. Transl. Med."}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802018305005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802018305005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:16:58Z","timestamp":1761178618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802018305005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":22,"alternative-id":["S1353802018305005"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2018.11.015","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase IIb, randomised, double-blind, placebo-controlled, dose-ranging investigation of the safety and efficacy of NTCELL\u00ae [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2018.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}